Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14423/SMJ.0000000000001701 | DOI Listing |
Alzheimers Dement
December 2024
Canadian Consortium on Neurodegeneration in Aging (CCNA), Montreal, QC, Canada; 3560 Bathurst Street Toronto, 3560 Bathurst Street Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada.
Involvement of caregivers in dementia research is an admirable goal. Involvement of caregivers in care planning for patients and people living with dementia, is essential to good medicine. However, it is important to assess and realistically consider areas where researchers and caregivers, and physicians and caregivers, may disagree.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Background: Alzheimer's disease is estimated to reach 139 million people by 2050, with an increase in people living with functional limitations caused by the disease (Alzheimer's Disease International). However, telerehabilitation presents a promising solution to improve functional outcomes in patients with Alzheimer's disease. This systematic review investigates the use of telerehabilitation therapies worldwide for the treatment of Alzheimer's disease and cognitive impairments.
View Article and Find Full Text PDFClin Kidney J
January 2025
Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz, Madrid, Spain.
Chimeric antigen receptor T (CAR-T) cell therapy, an emerging personalized immunotherapy for various haematologic malignancies, autoimmune diseases and other conditions, involves the modification of patients' T cells to express a chimeric antigen receptor that recognizes tumour or autoimmune cell antigens, allowing CAR-T cells to destroy cancerous and other target cells selectively. Despite remarkable clinical improvements in patients, multiple adverse effects have been associated with CAR-T cell therapy. Among the most recognized adverse effects are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and tumour lysis syndrome.
View Article and Find Full Text PDFMediastinum
December 2024
Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, San Diego, CA, USA.
Background And Objective: Diagnosis of pathology in the mediastinum has proven quite challenging, given the wide variability of both benign and malignant diseases that affect a diverse array of structures. This complexity has led to the development of many different non-invasive and invasive diagnostic modalities. Historically, diagnosis of the mediastinum has relied on different imaging modalities such as chest X-ray, computed tomography (CT), magnetic resonance imaging, and positron emission topography.
View Article and Find Full Text PDFMediastinum
September 2024
Divisions of Critical Care, Pulmonary and Sleep Medicine, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center (UTHealth), Houston, TX, USA.
Background And Objective: There are several benign processes that affect the mediastinum with considerable morbidity that may range from reactive entities to neoplastic disorders. This review article will focus on non-neoplastic benign mediastinal diseases which include large vessel vasculitis such as Takayasu and giant cell arteritis, mediastinal granulomas, fibrosing mediastinitis and mediastinal infections. These diseases can cause significant morbidity and mortality; therefore, we aim to familiarize readers with the pathophysiology, epidemiology and diagnosis of these mediastinal diseases and provide an update on the treatment options available.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!